Cash Position: Cash, cash equivalents, and marketable securities totaled $379.2 million as of June 30, 2025. Following receipt of the $195.0 million upfront payment from Novo Nordisk in July, Septerna ...

By successfully establishing a foothold in Singapore, Shawarma Shack aims to demonstrate the viability and appeal of its fast ...

Announced positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally ...

We are pleased with the progress we’ve made this past quarter, underscored by the encouraging tolerability and PK data from the Phase 1 trials of ...

Monte Rosa Therapeutics (NASDAQ:GLUE), a biotechnology company developing molecular glue degrader therapies, announced results for the second quarter on August 7, 2025. The stando ...

For all 127 of its Formula E races, Jaguar TCS Racing has had two constants: Mitch Evans and James Barclay. Now, however, it ...

Traversa communicated that the company intends "to initiate a Phase III study for NDV-01 in the first half of 2026" and to start a "proof-of-concept study in PWS in the first half of 2026" for ...

ABCL-575’s predicted dosing schedule of every six months is enabled by a "human half-life of approximately 67 days," as ...

Operator: Good morning, ladies and gentlemen, and welcome to the Scholar Rock Second Quarter 2025 Business Update Conference Call. [Operator Instructions] This call is being recorded […] ...

GAAP net loss per share was $(11.29) for Q2 2025, missing the consensus GAAP EPS estimate of $(4.62) by a wide margin, mainly due to a $17.0 million up-front license fee. NextCure advanced both its ...

Compugen advances COM701 in ovarian cancer with strong partners, key catalysts ahead, and funding into 2027. Find out why ...

In April 2025, Monte Rosa presented preclinical data on the potential of its highly selective CDK2-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the ...